Buy ETFs

Radiopharmaceuticals: Transforming Cancer Care

By David K. Song, MD, PhD, CFA
Investment Partner
February 15, 2024

Radiopharmaceuticals, or radioligand therapies, stand at the forefront of cancer treatment innovation. These therapies employ radioactive compounds engineered to a targeting molecule that can seek out and destroy cancer cells with remarkable precision, using both alpha and beta particles. The journey begins with diagnostics, employing milder radioactive compounds for detection imaging, and progresses to more potent therapeutics. Challenges include safe manufacturing and securing essential radionuclides.

Chart 4

Radiopharmaceuticals offer the advantage of precise cancer cell targeting, sparing healthy tissue. Breakthroughs like Lutathera and Pluvicto have significantly improved patient outcomes. Pluvicto, for example, extended radiographic progression-free survival to 8.7 months, a substantial improvement over conventional treatments.

A promising avenue is the combination of radiopharmaceuticals with immunotherapy, potentially leading to revolutionary advances in cancer care. Furthermore, there's a long-term vision where radiopharmaceuticals may replace traditional radiotherapy.

Prostate cancer has been a key market already measuring $1.6 billion in diagnostics and therapeutics. The next phase involves introducing radiopharmaceuticals earlier in treatment and expanding their application to multiple cancer types, potentially creating a blockbuster market.

Read more about Radiopharmaceuticals, the companies leading the charge in this transformative field, and other revolutionary oncology innovations in our latest report: temaetfs.com/tema-insights-oncology-canc.

CANC

Oncology ETF

FUND PAGE

TOLL

Monopolies and Oligopolies ETF

RSHO

American Reshoring ETF

LUX

Luxury ETF

HRTS

GLP-1, Obesity & Cardiometabolic ETF

MNTL

Neuroscience and Mental Health ETF

VOLT

Electrification ETF

VIEW

Featured

American Reshoring and the U.S. Election

Read More

October Monthly Webinar - Mag Seven Got You Down?

Read More

Why pricing is not a risk to the GLP-1 market opportunity?

Read More

How big could the weight loss market be?

Read More

Risk Information

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com.
Read the prospectus carefully before investing.

Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.

Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.

Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.

Oncology Companies Risk: Oncology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company's valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable.

The stock prices of oncology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable. Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained.

Investing in Foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.

Because the Fund evaluates ESG factors to assess and exclude certain investments for non-financial reasons, the Fund may forego some market opportunities available to funds that do not use these ESG factors.

Tema Global Limited serves as the investment adviser to Tema Oncology ETF (the “Fund”), and NEOS Investments, LLC serves as a sub-adviser to the Fund. The Fund is distributed by Foreside Fund Services LLC, which is not affiliated with Tema Global Limited nor NEOS Investments, LLC. Check the background of Foreside on FINRA’s BrokerCheck.